Compare Repligen Corporation Common Stock (RGEN) vs Viavi Solutions Inc. Common Stock (VIAV) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Repligen Corporation Common Stock vs Viavi Solutions Inc. Common Stock — how do they compare? Repligen Corporation Common Stock trades at $178.15 (market cap $11.14B), while Viavi Solutions Inc. Common Stock trades at $37.33 (market cap $10.15B). The key difference: Repligen Corporation Common Stock and Viavi Solutions Inc. Common Stock are close in size by market cap, and Repligen Corporation Common Stock is trading nearer its 52-week high, Viavi Solutions Inc. Common Stock nearer its low. Which is the better fit depends on your goals — on Pluang, investors hold Repligen Corporation Common Stock for 0 Days and Viavi Solutions Inc. Common Stock for 6 Days on average.
| RGEN | VIAV | |
|---|---|---|
Market Cap | $11.14B | $10.15B |
Volume | 1,259,263 | 4,601,222 |
Sector | Health | Technology |
52-Week High | $194.57 | $55.33 |
52-Week Low | $102.87 | $13.01 |
Typical Hold Time | 0 Days | 6 Days |
Enterprise Value | $11.02B | $10.20B |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
RGEN trades at $175.42, up 1.66% today, with a neutral technical signal and key support at $173. The stock has consistently beaten earnings estimates in recent quarters, with Q3 2026 results due October 27. Revenue grew to $738.26M in 2025, though net income margin is modest at 5.29%. The company recently completed the acquisition of BioLife Solutions, signaling strategic expansion.
Outlook remains positive with strong analyst support (91.67% buy ratings) and a consensus price target of $173.86, though high valuation multiples (P/E 240.34) pose a risk. Earnings growth and integration of acquisitions are key catalysts, but investors face execution risks and market volatility.
VIAVI Solutions (VIAV) trades at $41.28, down 1.13% on the day, with mixed technical signals showing bearish overall momentum but bullish moving averages. The company demonstrates strong revenue growth with fiscal 2026 revenue reaching $1.52B (up 40% YoY) and has beaten earnings estimates for three consecutive quarters. Recent developments include a U.S. Army contract for defense testing and expanded partnerships in network validation, positioning VIAV for growth in AI data center and defense markets.
While analyst consensus remains strongly bullish with a $60.25 price target (78.95% buy ratings), investors face risks from negative net income margins (-2%) and elevated valuation metrics (P/S 6.24, EV/EBITDA 60.68). The stock's outlook depends on continued execution in high-growth segments and margin improvement to justify current valuations amid competitive pressures.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
No sentiment data available yet.
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Repligen Corporation Common Stock
Repligen Corporation develops and manufactures bioprocessing tools and technologies used in biologic drug manufacturing, including filtration and perfusion systems, chromatography columns and resins, and process analytics instruments. Its products support upstream and downstream production workflows for modalities such as monoclonal antibodies, mRNA, and viral vectors.
Read more on RGEN →About Viavi Solutions Inc. Common Stock
Viavi Solutions provides network testing, monitoring, and optical technologies. Its products help communications providers, equipment makers, and enterprises build and maintain networks.
Read more on VIAV →
